Posted: 11 April 2024
Patrys Limited a therapeutic antibody development company, is delighted to announce that new data from preclinical studies using PAT-DX1 and PAT-DX3 in animal models of the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis were presented by Dr Kim O’Sullivan from Monash University during the plenary session at the 21st International Vasculitis Workshop in Barcelona overnight.
Previously Patrys has reported results from a range of non-clinical studies which showed that its dexomabs suppress the formation of neutrophil extracellular traps (NETs). NETs are structures comprised of DNA strands and certain proteins produced by neutrophils (see press release entitled “New mechanism by which PAT-DX1 may reduce cancer metastasis”, 14 June 2022). Recent studies have indicated that NETs may play an important role in the establishment and maintenance of cancer cells, the spreading of cancer (metastasis) and in regulating inflammation.
As the formation of NETs is one of the underlying processes in the development of the autoimmune disease ANCA vasculitis, Dr O’Sullivan extended these findings by examining the impact of Patrys’ deoxymabs in an animal model of the disease. The key results from these studies include:
- PAT-DX1 and PAT-DX3 are both able to inhibit the formation of NETs in an animal model of ANCA vasculitis;
- Both deoxymabs reduced the level of inflammation and kidney injury in the animal model of ANCA vasculitis;
- However, neither PAT-DX1 nor PAT-DX3 has any detrimental effect on neutrophils indicating that their administration did not result in any suppression of the immune system.
‘We are pleased to present these important discoveries at the leading global meeting on vasculitis’ said Dr O’Sullivan. “We are particularly excited by the discovery that both PAT-DX1 and PAT-DX3 are able to reduce symptoms of inflammation without negatively impacting the immune system as this is one of the major side-effects of existing therapies of vasculitis.”
